Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ceforanide kinetics

E H Estey, S S Weaver, B M LeBlanc

    Clinical Pharmacology and Therapeutics
    |September 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

    Leukemia·2017
    Same author

    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

    Leukemia·2017
    Same author

    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

    Leukemia·2016
    Same author

    Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

    Leukemia·2016
    Same author

    Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

    Leukemia·2016
    Same author

    Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

    Leukemia·2015
    Same journal

    Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

    Clinical pharmacology and therapeutics·2026
    Same journal

    From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

    Clinical pharmacology and therapeutics·2026
    Same journal

    The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Ceforanide, a semisynthetic cephalosporin, demonstrated favorable pharmacokinetics in cancer patients, showing a prolonged serum half-life and broad-spectrum activity. These findings suggest potential clinical utility for this antibiotic in oncology settings.

    Area of Science:

    • Pharmacology
    • Oncology
    • Infectious Diseases

    Background:

    • Cephalosporins are a class of beta-lactam antibiotics widely used for bacterial infections.
    • Ceforanide is a semisynthetic cephalosporin with potential for clinical application.

    Purpose of the Study:

    • To evaluate the pharmacokinetics and safety of ceforanide in cancer patients.
    • To determine optimal dosing regimens for ceforanide.

    Main Methods:

    • Intravenous administration of ceforanide at different doses and schedules (500 mg every 6 hr, 1 gm every 12 hr, continuous infusion).
    • Measurement of serum and urinary concentrations of ceforanide.
    • Assessment of serum half-life and toxicity.

    Main Results:

    Related Experiment Videos

    • Peak serum concentrations ranged from 44.7 to 91.8 µg/ml depending on the dose and schedule.
    • Mean serum concentrations after 12 hours were 5.6–6.5 µg/ml with 1 gm every 12 hr.
    • Continuous infusion maintained concentrations above 34.2 µg/ml for 7–8 days.
    • Serum half-life was prolonged (2.2–2.9 hr) compared to other cephalosporins.
    • No serious toxicity was observed.

    Conclusions:

    • Ceforanide exhibits favorable pharmacokinetic properties, including a long half-life and broad-spectrum activity.
    • The drug is well-tolerated in cancer patients.
    • These characteristics suggest ceforanide's potential clinical utility in treating infections in this population.